Skip to main content
Clinical Trials/RBR-2h5rwgb
RBR-2h5rwgbRecruitingPhase 4

Genicular artery embolization using imipenem/cilastatin versus microsphere for ostheoartritis: a randomized clinical trial

Invasc - Instituto Vascular de Passo Fundo0 sitesStarted: July 20, 2021Last updated:
Conditions

Trial Snapshot

Phase
Phase 4
Status
Recruiting
Sponsor

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Intervention

Eligibility Criteria

Ages
0 to 0 (—)

Inclusion Criteria

  • Diagnosis of knee ostheoartritis; Knee pain for more than 6 month; Refractory to conservative treatment - at least 3 months of physical therapy and/or parenteral pain medication and/or corticosteroid knee infiltration with no clinical improvement; Kellgreen-Lawrence classification I to III in the knee X-ray; Comproved sinovitis in the magnetic resonance; Wiling to participate and to sign the consentment term; Willing to follow up; It has to be in hospital due to refractory knee pain.

Exclusion Criteria

  • Indication to total knee replacement, Kellgreen-Lawrence grade IV; No conservative measure performed before enrollment; Previous knee arthroplasty; Patients with Rheumatoid arthritis or infectious arthritis; Patients with fybromialgia; Deposit corticosteroid 30 days prior to embolization; Patients with no cognitive conditions to participate to the procedure, informing where are the pain areas; Comproved allergy to iodine ou to any of the embolization agents; Comproved coagulopathy; Prothrombin activity time <50%; INR >1,5; Platelet count <50.000/mm3; Serum creatinin > 2,0mg/dl; Not to sign consentment term or not to willing to participate of the study.

Investigators

Sponsor
Invasc - Instituto Vascular de Passo Fundo

Similar Trials